Illumina, Inc. $ILMN Stake Lifted by Spyglass Capital Management LLC

Spyglass Capital Management LLC boosted its stake in Illumina, Inc. (NASDAQ:ILMN) by 25.0% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 698,565 shares of the life sciences company’s stock after buying an additional 139,508 shares during the period. Illumina accounts for approximately 3.8% of Spyglass Capital Management LLC’s investment portfolio, making the stock its 11th largest holding. Spyglass Capital Management LLC owned 0.45% of Illumina worth $66,650,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently modified their holdings of the company. Envestnet Portfolio Solutions Inc. lifted its position in Illumina by 0.8% in the 2nd quarter. Envestnet Portfolio Solutions Inc. now owns 12,074 shares of the life sciences company’s stock valued at $1,152,000 after purchasing an additional 99 shares during the last quarter. Parkside Financial Bank & Trust grew its position in Illumina by 65.7% in the 2nd quarter. Parkside Financial Bank & Trust now owns 290 shares of the life sciences company’s stock worth $28,000 after purchasing an additional 115 shares during the last quarter. Moors & Cabot Inc. increased its stake in shares of Illumina by 2.5% in the first quarter. Moors & Cabot Inc. now owns 5,855 shares of the life sciences company’s stock valued at $465,000 after purchasing an additional 145 shares during the period. Arkadios Wealth Advisors raised its holdings in shares of Illumina by 1.7% during the second quarter. Arkadios Wealth Advisors now owns 9,130 shares of the life sciences company’s stock valued at $871,000 after buying an additional 157 shares during the last quarter. Finally, Tokio Marine Asset Management Co. Ltd. boosted its position in shares of Illumina by 3.0% during the first quarter. Tokio Marine Asset Management Co. Ltd. now owns 5,604 shares of the life sciences company’s stock worth $445,000 after buying an additional 164 shares during the period. Institutional investors and hedge funds own 89.42% of the company’s stock.

Illumina Price Performance

Shares of Illumina stock opened at $131.39 on Monday. Illumina, Inc. has a 52 week low of $68.70 and a 52 week high of $153.06. The company has a current ratio of 1.81, a quick ratio of 1.41 and a debt-to-equity ratio of 0.66. The stock has a market cap of $20.08 billion, a PE ratio of 16.63, a price-to-earnings-growth ratio of 2.34 and a beta of 1.42. The company’s 50-day moving average price is $107.97 and its two-hundred day moving average price is $99.45.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Thursday, October 30th. The life sciences company reported $1.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.16 by $0.18. Illumina had a net margin of 29.36% and a return on equity of 28.93%. The company had revenue of $1.08 billion for the quarter, compared to analysts’ expectations of $1.07 billion. During the same quarter in the previous year, the company posted $1.14 EPS. The business’s revenue was up .4% compared to the same quarter last year. Illumina has set its FY 2025 guidance at 4.650-4.750 EPS. As a group, sell-side analysts anticipate that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms recently commented on ILMN. Daiwa America cut Illumina from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 12th. Barclays increased their price target on Illumina from $95.00 to $100.00 and gave the stock an “underweight” rating in a research note on Friday, October 31st. Cowen restated a “hold” rating on shares of Illumina in a research note on Friday, October 31st. TD Cowen upped their price objective on shares of Illumina from $110.00 to $115.00 and gave the stock a “hold” rating in a report on Friday, October 31st. Finally, Morgan Stanley raised their target price on shares of Illumina from $100.00 to $105.00 and gave the company an “equal weight” rating in a research note on Monday, August 4th. Five research analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $115.00.

Insider Activity

In related news, Director Scott Gottlieb acquired 500 shares of the business’s stock in a transaction dated Monday, November 3rd. The stock was bought at an average price of $122.13 per share, for a total transaction of $61,065.00. Following the transaction, the director owned 12,523 shares of the company’s stock, valued at approximately $1,529,433.99. The trade was a 4.16% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 2.60% of the company’s stock.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.